Australia’s CSL reaffirms commitment to making AstraZeneca COVID vaccine

imageStock Markets9 minutes ago (Oct 13, 2021 08:16PM ET)

(C) Reuters. FILE PHOTO: Vials labelled “Astra Zeneca COVID-19 Coronavirus Vaccine” and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/File Photo

(Reuters) – Australian biotech CSL (OTC:CSLLY) said on Thursday it was committed to its agreement for the production of about 50 million doses of AstraZeneca (NASDAQ:AZN)’s COVID-19 vaccine into 2022.

The announcement came after a media report said the British drugmaker’s vaccine, Vaxzevria, will no longer be manufactured in Australia due to demand for vaccines of Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA). [nL4N2R91XR]

Pfizer and Moderna have established a market dominance by using mRNA-based COVID-19 vaccine technology to fight the pandemic.

CSL, in a brief statement, added that more than 20 million of the doses have already been produced, and it is expected that the remaining production will be completed early next year.

Cafes, gyms and restaurants in Sydney welcomed back fully vaccinated customers earlier this week after nearly four months of a lockdown, as Australia aims to begin living with the coronavirus and gradually reopen with high rates of inoculation.

Australia’s CSL reaffirms commitment to making AstraZeneca COVID vaccine

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles

Alphabet Q3 Results Top Estimates as Advertising Growth Swells

Sign In/Free Sign Up 0 Stock Markets8 minutes ago (Oct 26, 2021 04:15PM ET) (C) Reuters. Alphabet A Earnings, Revenue Beat in Q3 By Yasin...

Major issues unresolved as Democrats in U.S. Congress seek deal on spending bill

2/2 (C) Reuters. FILE PHOTO: U.S. Senator Joe Manchin (D-WV) walks through the U.S. Capitol in Washington, U.S., October 21, 2021. REUTERS/Elizabeth Frantz/File Photo 2/2 By Richard...

Oil Near Highs As Trade Awaits Weekly U.S. Inventory Snapshot

Commodities39 minutes ago (Oct 26, 2021 03:44PM ET) (C) Reuters. By Barani Krishnan Investing.com - Crude prices were near multi-year highs on Tuesday as market participants...

Latest Posts

Stay in touch

Join the exclusive subscription today and get premium articles for free

Categories